NCT06299163 - NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

April 18, 2025

Study Completion Date

April 18, 2025

Conditions

Ovarian CarcinomaFallopian Tube CarcinomaPeritoneal CarcinomaEndometrial CancerAdenocarcinoma of LungTriple Negative Breast CancerLiposarcomaLeiomyosarcomaMesothelioma, MalignantAdenocarcinoma - Gastroesophageal Junction (GEJ)Adenocarcinoma of the StomachMelanoma, MalignantRenal Cell Carcinoma

Interventions

BIOLOGICAL

NM32-2668

Anti-ROR1/Anti-Cluster of Differentiation 3 (CD3)/Anti-Human Serum Albumin (HSA) Tri-Specific Antibody

Trial Locations (11)

15232

University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh

27710

Duke University, Durham

29425

Medical University of South Carolina (MUSC), Charleston

35294

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt University Medical Center, Nashville

44195

Cleveland Clinic, Cleveland

53226

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

60637

The University of Chicago Medical Center (UCMC), Chicago

75230

Mary Crowley Cancer Research, Dallas

90033

USC Norris Comprehensive Cancer Center, Los Angeles

02903

Lifespan Cancer Institute at Rhode Island Hospital, Providence